Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Drug Development for Skin Cancer
share announcement

Advances in Drug Development for Skin Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1796

Special Issue Editor

Dr. Rajan P. Kulkarni

E-Mail Website
Guest Editor
Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA
Interests: melanoma; immune checkpoint inhibitor; targeted therapy

Special Issue Information

Dear Colleagues,

Skin cancers are the most common type of cancers worldwide. While non-melanoma skin cancers (NMSC) are the most frequent, melanomas have a higher mortality rate if untreated. Although surgical treatment is often curative for skin cancer, topical and/or systemic agents are often necessary as well. The past decade has seen a rapid increase in the number and types of treatments available for treatment of skin cancers, with many more agents under development. Here, we are interested in both novel agents and treatment strategies for skin cancers (both melanomas and non-melanoma skin cancers). Articles of interest will thus span both novel agents in development and the repurposing of other agents that can be utilized towards skin cancer treatment or prevention. Of special interest are advances that deal with immune modulation for treatment of skin cancer, though studies focusing on targeted agents are also welcomed. We are interested in all aspects of drug development, from pre-clinical and in vitro studies to clinical studies, including mechanistic studies. We also welcome articles that discuss side effects from treatments for skin cancer and potential strategies to mitigate them.

Dr. Rajan P. Kulkarni
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • non-melanoma skin cancer
  • squamous cell carcinoma
  • basal cell carcinoma
  • immunotherapies
  • targeted therapies
  • adverse events
  • mechanisms

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 3103 KiB  
Communication
Comparison of Immunotherapy versus Targeted Therapy Effectiveness in BRAF-Mutant Melanoma Patients and Use of cGAS Expression and Aneuploidy as Potential Prognostic Biomarkers
by Zachary Garrison, Terri Clister, Eric Bleem, Elizabeth G. Berry and Rajan P. Kulkarni
Cancers 2024, 16(5), 1027; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16051027 - 01 Mar 2024
Viewed by 684
Abstract
BRAF-mutant melanoma patients can be treated with targeted therapy or immunotherapies, and it is not clear which should be provided first. Targeted treatments do not work in up to one-third of cases, while immunotherapies may only be effective in up to 60% and [...] Read more.
BRAF-mutant melanoma patients can be treated with targeted therapy or immunotherapies, and it is not clear which should be provided first. Targeted treatments do not work in up to one-third of cases, while immunotherapies may only be effective in up to 60% and come with a high risk of immune-related side effects. Determining which treatment to provide first is thus of critical importance. Recent studies suggest that chromosomal instability and aneuploidy and cyclic GMP-AMP synthase (cGAS) can act as biomarkers for cancer severity and patient outcome. Neither potential biomarker has been extensively studied in melanoma. We examined 20 BRAF-mutant melanomas treated with immunotherapy or targeted therapy and measured chromosomal aneuploidy and cGAS expression levels. Treatment type, aneuploidy, and cGAS expression were correlated with progression-free survival (PFS) in these patients. Those treated with immunotherapy first had significantly better outcomes than those treated with targeted therapy, suggesting immunotherapy should be strongly considered as the first-line therapy for patients bearing BRAF-mutant melanoma. We found that there was no correlation of aneuploidy with outcome while there was some positive correlation of cGAS levels with PFS. Further studies are needed to confirm these findings and to test other potential biomarkers. Full article
(This article belongs to the Special Issue Advances in Drug Development for Skin Cancer)
►▼ Show Figures

Figure 1

18 pages, 3715 KiB  
Article
Cancer-Preventive Activity of Argemone mexicana Linn Leaves and Its Effect on TNF-α and NF-κB Signalling
by Sunanda Kulshrestha, Anjana Goel, Nikhat J. Siddiqi, Sabiha Fatima and Bechan Sharma
Cancers 2023, 15(23), 5654; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15235654 - 30 Nov 2023
Viewed by 712
Abstract
Skin cancer is the 5th most common cancer in Western countries with a surge in case occurrences making it a global burden on healthcare systems. The present study aims to evaluate the cancer-preventive activity of an ethanolic extract of Argemone mexicana Linn leaves [...] Read more.
Skin cancer is the 5th most common cancer in Western countries with a surge in case occurrences making it a global burden on healthcare systems. The present study aims to evaluate the cancer-preventive activity of an ethanolic extract of Argemone mexicana Linn leaves (AML). The DMBA/TPA method was used to induce skin cancer in mice. Experimental animals were divided into three pretreatment groups of 100 mg/kg BW, 250 mg/kg BW, and 500 mg/kg BW of AML extract, and feeding was continued during the induction process. In the fourth group, 500 mg/kg BW AML extract treatment was started along with the cancer induction. The analyses were performed on the basis of the time period of in-tumour induction incidence, haematological parameters, histopathology and augmentation of TNF-α secretion and the NF-κB (p65 subunit) signalling pathway. The AML extract resisted and delayed tumour formation for up to 8 weeks in the 500 mg/kg BW pretreated group as compared to 4 weeks in the negative control group. The tumour burden varied in a dose-dependent manner in the different groups. On the 60th day, a significantly high burden (p < 0.001) was observed in the negative control group and the 100 mg/kg BW group. The study was validated by investigating the expression of TNF-α and the p65 subunit of the NF-κB signalling pathway, which were found to be reduced significantly in a dose-dependent manner and significantly reduced (p < 0.001) in the 500 mg/kg BW group as compared to negative control group. The 500 mg/kg BW pretreated group was found to have significant results in comparison to the 500 mg/kg BW post-treatment group. The study revealed the effective cancer preventive activity of Argemone mexicana Linn leaves (AML) in the mouse model and paved a pathway for molecular approaches which could be explored more in future studies. Full article
(This article belongs to the Special Issue Advances in Drug Development for Skin Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop